Table 3 Muscular and cutaneous activity evaluation and medications in use by JDM patients at each study visit
Study visitsa | V1b | V2 | V3 | V4 | V1b | V2 | V3 | V4 | V1b | V2 | V3 | V4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
JDM groups | A + B (n = 27) | A + B (n = 27) | A + B (n = 25) | A + B (n = 20) | C (n = 15) | C (n = 15) | C (n = 15) | C (n = 6) | Total (n = 42) | Total (n = 42) | Total (n = 40) | Total (n = 26) |
Muscular activity | ||||||||||||
CMAS, median | 52 | 52 | 52 | 52 | 37 | 42 | 46 | 43 | 50 | 51,5 | 50 | 50 |
Cutaneous activity | ||||||||||||
Rash, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (60) | 7 (46.7) | 4 (26.7) | 1 (16.7) | 9 (21.4) | 7 (16.7) | 4 (10) | 1 (3.8) |
Gottron’s papules, n (%) | 0 (0.0) | 0 (0.0) | 1 (4.0) | 0 (0.0) | 12 (80) | 9 (60) | 9 (60) | 3 (50) | 12 (28.6) | 9 (21.4) | 10 (25) | 3 (11.5) |
Heliotropo, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (46.7) | 4 (26.7) | 5 (33.3) | 1 (16.7) | 7 (16.7) | 4 (9.5) | 5 (12.5) | 1 (3.8) |
Medications in use | ||||||||||||
Costicosteroids, n (%) | 5 (18.8) | 5 (18.5) | 5 (20.0) | 5 (25.0) | 15 (100) | 15 (100) | 15 (100) | 6 (100) | 20 (47.6) | 20 (47.6) | 19 | 11 (42.3) |
Oral Prednisone, n (%) [median dose] | 5 (18.5) [15] | 5 (18.5) [5] | 5 (20.0) [10] | 5 (25.0) [5] | 12 (80) [20] | 13 (86.7) [10] | 12 (80) [10] | 5 (83.3) [10] | 17 (40,5) [15] | 18 (42.9) [10] | 16 (40) [10] | 10 (38.5) [6.25] |
IV Methylprednisolone, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (33.3) | 3 (20) | 3 (20) | 1 (16.7) | 5 (11.9) | 3 (7.1) | 3 (7,5) | 1 (3.8) |
Hydroxychloroquine, n (%) | 9 (33.3) | 8 (29.6) | 8 (32.0) | 4 (20.0) | 8 (53.3) | 10 (66.7) | 10 (66.7) | 4 (66.7) | 17 (40.5) | 18 (42.9) | 18 (45) | 8 (30.8) |
Methotrexate, n (%) | 6 (22.2) | 5 (18.8) | 6 (24.0) | 4 (20.0) | 9 (60) | 10 (66.7) | 9 (60) | 3 (50) | 15 (35.7) | 15 (35.7) | 15 (37.5) | 7 (26.9) |
Azathioprine, n (%) | 5 (18.8) | 4 (14.8) | 5 (20.0) | 3 (15.0) | 3 (20) | 3 (20) | 3 (20) | 2 (33.3) | 8 (19) | 7 (16.7) | 8 (20) | 5 (19.2) |
Mycophenolate Mofetil, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (6.7) | 1 (6.7) | 2 (13.3) | 1 (16.7) | 1 (2.4) | 1 (2.4) | 2 (5) | 1 (3.8) |
Cyclosporine, n (%) | 3 (11.1) | 3 (11.1) | 3 (12.0) | 3 (15.0) | 4 (26.7) | 4 (26.7) | 3 (20) | 0 (0.0) | 7 (16.7) | 7 (16.7) | 6 (15) | 3 (11.5) |
Cyclophosphamide, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (6.7) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 1 (2.4) | 1 (2.4) | 0 (0.0) | 0 (0.0) |
Human Immunoglobulin, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (13.3) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 2 (4.8) | 2 (4.8) | 0 (0.0) | 0 (0.0) |
No medication, n (%) | 11 (40.7) | 13 (48.1) | 11 (44.0) | 8 (40.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (26,2) | 13 (31) | 11 (27.5) | 8 (30.8) |